Next Article in Journal
Deficiency in STAT1 Signaling Predisposes Gut Inflammation and Prompts Colorectal Cancer Development
Next Article in Special Issue
Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia
Previous Article in Journal
Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer
Previous Article in Special Issue
Bridging Strategies to Allogeneic Transplant for Older AML Patients
Review

Autologous Transplantation for Older Adults with AML

1
Department of BioMedical Research, University of Bern, 3010 Berne, Switzerland
2
Department of Hematology, University of Bern, 3010 Berne, Switzerland
3
Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Berne, Switzerland
*
Author to whom correspondence should be addressed.
Received: 13 July 2018 / Revised: 17 September 2018 / Accepted: 17 September 2018 / Published: 19 September 2018
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. Even if standard intensive chemotherapy induces morphologic complete remission (CR1), relapses in older AML patients are common leading to poor long-term survival outcomes. Since autologous hematopoietic stem cell transplantation (HCT) offers distinct anti-leukemic effectiveness while avoiding graft-versus-host disease associated with allogeneic transplantation, it represents an option for consolidation treatment in selected older AML patients. However, prospective studies in older AML patients assessing the benefit of autologous HCT compared to chemotherapy consolidation or allogeneic transplantation are lacking. Consequently, clinicians face the dilemma that there is considerable ambiguity on the most appropriate consolidation treatment for older AML patients in CR1. This review highlights the possible role of autologous HCT for consolidation in older AML patients reaching CR1 after induction treatment. View Full-Text
Keywords: AML; autologous; transplantation; older; elderly; outcome; survival; review AML; autologous; transplantation; older; elderly; outcome; survival; review
Show Figures

Figure 1

MDPI and ACS Style

Mueller, B.U.; Seipel, K.; Bacher, U.; Pabst, T. Autologous Transplantation for Older Adults with AML. Cancers 2018, 10, 340. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10090340

AMA Style

Mueller BU, Seipel K, Bacher U, Pabst T. Autologous Transplantation for Older Adults with AML. Cancers. 2018; 10(9):340. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10090340

Chicago/Turabian Style

Mueller, Beatrice U., Katja Seipel, Ulrike Bacher, and Thomas Pabst. 2018. "Autologous Transplantation for Older Adults with AML" Cancers 10, no. 9: 340. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10090340

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop